surmount 3 tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase trial ECO 2026: SURMOUNT-MAINTAIN proves tirzepatide

It also reduces hunger signals to the brain, making it easier to follow a lower-calorie eating plan

Consult a healthcare provider for medical advice before using either medication

Step 3: Treatment

Similarly, as seen in non-syndromic obesity ( Type 2 diabetes mellitus is a common obesity-related complication in PWS and is diagnosed in 7-24% of adults with PWS compared to 5-7% in the general population ( Growth hormone deficiency is diagnosed in between 40 and 100% of patients with PWS

Track subjective markers energy stability, post-meal glucose response if you have a glucose monitor, appetite changes, body weight, waist circumference but understand that the primary endpoints are blood markers measured at week 12, not subjective feelings during the trial

Data analysed by one-way ANOVA, multiple comparison, Bonferroni post hoc test ( e , f , k and l ) and two-way repeated measures ANOVA to assess main effects of treatment ( b , d , h - j , n and p )